71 – 80 of 657
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Autologous cell therapy - A new concept to eradicate inhibitors in haemophilia
- Contribution to journal › Letter
-
Mark
Impact of dronedarone on patients with atrial fibrillation and diabetes : A sub-analysis of the ATHENA and EURIDIS/ADONIS studies
- Contribution to journal › Article
-
Mark
Biomarkers of complement and platelet activation are not correlated with the one or twenty-four hours corrected count increments in prophylactically platelet transfused hematological patients : a prospective cohort study
- Contribution to journal › Article
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
- Contribution to journal › Article
-
Mark
Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction : a post-hoc analysis of the ATHENA trial
- Contribution to journal › Article
-
Mark
International consensus recommendations on the management of people with haemophilia B
- Contribution to journal › Scientific review
-
Mark
Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function : Post hoc analyses of the EURIDIS-ADONIS trials
- Contribution to journal › Article
-
Mark
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81–8973
- Contribution to journal › Article
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
- Contribution to journal › Article
-
Mark
Thrombotic Risk Determined by Protein C Receptor (PROCR) Variants among Middle-Aged and Older Adults : A Population-Based Cohort Study
- Contribution to journal › Article
